Global Biologic Products Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Biologic Products Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Biological products are used to diagnose, prevent, treat, and cure diseases and medical conditions. Biological products are a diverse category of products and are generally large, complex molecules. These products may be produced through biotechnology in a living system, such as a microorganism, plant cell, or animal cell, and are often more difficult to characterize than small molecule drugs. There are many types of biological products approved for use in the United States, including therapeutic proteins (such as filgrastim), monoclonal antibodies (such as adalimumab), and vaccines (such as those for influenza and tetanus).

Market Overview:

The latest research study on the global Biologic Products market finds that the global Biologic Products market reached a value of USD 561091.0 million in 2022. It’s expected that the market will achieve USD 1085200.0 million by 2028, exhibiting a CAGR of 11.62% during the forecast period.

In the short term, the profits of the biologic product industry will increase and the development prospect will be better

The main feature of COVID-19 is that it is extremely contagious and involves a large population, but the mortality rate is relatively low. At present, there are no factors such as special drugs, and the epidemic may continue for some time. With the increasing number of infected people worldwide, the government, research institutions and related companies have continuously increased research on related therapeutic drugs and biological agents. The epidemic will benefit the pharmaceutical industry in the short term. In the short term, with the increase in the number of diagnoses, due to factors such as increased demand for treatment and increased public attention to biological products, the short-term rise of related companies has made the prospects for the biological product industry better.

Long-term biologic product industry will develop steadily

The COVID-19 epidemic has infected many people, and its spread and scope far exceed SARS. Countries around the world continue to strengthen prevention and control to control the spread of epidemics, but the impact of epidemics on various industries is different. In the long run, COVID-19 will promote the deepening of medical reform. At the same time, with the increased awareness of medical treatment and the rise of the prevalence of chronic diseases, the government and various social institutions have increased investment in biological products, and the continuous development of biological agents and other factors will make the biological product industry develop steadily.

Region Overview:

Geographically, North America held the largest market share – 49.12% in 2022.

Company Overview:

Pfizer Inc. is one of the major players operating in the Biologic Products market, holding a share of 9.69% in 2023.

Pfizer Inc.

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

F Hoffman La Roche

F. Hoffmann-La Roche AG provides in-vitro diagnostics and drugs for cancer and transplantation. The Company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology.

Segmentation Overview:

The Diagnostic Centers segment by type showed a value growth of 12.58% in 2022.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Biologic Products market covered in Chapter 3:

Celltrion
Eli Lilly & Company
Sanofi
Pfizer Inc.
Novo Nordisk AS
Abbvie Inc.
Gilead
Merck & Co. Inc
Amgen
Johnson & Johnson Services Inc.
F Hoffman La Roche

In Chapter 4 and Chapter 14.2, on the basis of types, the Biologic Products market from 2018 to 2029 is primarily split into:

Platelet Rich Plasma
Interleukin Receptor Antagonist Protein
Hyaluronic Acid
Stem Cell Therapy
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Biologic Products market from 2018 to 2029 covers:

Hospitals
Clinics
Diagnostic Centers
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)